A. PatriciaCampbell Ph.D.

Partner

(T) + 1.650.687.4138

Patricia Campbell has more than 10 years of experience counseling clients in all aspects of patent portfolio development in the pharmaceutical and biotechnology sectors. This includes for small molecule pharmaceuticals, antibodies and antibody-drug conjugates, diagnostics, enzyme replacements, and in silico screening methods for drug identification and development, among others. She has prosecuted some of the most valuable patent portfolios covering approved products from several of the world's premier biotechnology/pharmaceutical companies.

In addition to patent procurement and portfolio management, Patricia advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition. She also has experience with inter partes review proceedings and oppositions before the European Patent Office. Her representative life sciences clients include AbbVie, BioMarin Pharmaceutical, Genentech, NGM Biopharmaceuticals, and Jazz Pharmaceuticals, as well as other start-up companies, established companies, academic institutions, and investment firms.

Prior to practicing law, Patricia was a tenured associate professor in the Department of Medicinal Chemistry at the University of Washington, where she served as principal investigator on research projects funded by the National Institutes of Health and the Department of Defense. Her research programs included structure-based drug design and mechanistic studies of drug-drug interactions.

Patricia is a member of the American Bar Association and the IP Inn of Court.

Experience

  • Rain Therapeutics expands patent portfolio related to clinical stage cancer therapiesJones Day advised Rain Therapeutics Inc. in connection with global patent portfolio development related to a hypoxia-activated prodrug of a potent pan-HER inhibitor, Tarloxotinib (Tarlox), for the treatment of non-small cell lung cancer in patients with EGFR and HER exon 20 insertion mutations.
  • Global Blood Therapeutics develops patent portfolio of small molecule drug candidates for treatment of sickle cell diseaseJones Day represents Global Blood Therapeutics, Inc. in patent prosecution of small molecule drug candidates for treatment of sickle cell disease.
  • Scynexis launches public offering of Common StockJones Day led a team that handled the IP diligence for a follow-on public offering of common stock for Scynexis, Inc., a Research Triangle Park, North Carolina, pharmaceutical company committed to the discovery, development, and commercialization of novel anti-infectives.
  • Celgene files declaratory judgment action against CyclacelJones Day represents plaintiff Celgene Corporation in a declaratory judgment action for non-infringement and invalidity of four Cyclacel Pharmaceuticals, Inc. patents related to certain depsipeptides and uses thereof.
  • BioMarin acquires LEAD TherapeuticsJones Day advised BioMarin Pharmaceutical, Inc. in connection with the acquisition of LEAD Therapeutics, Inc., a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.
  • Ambit Biosciences develops patent portfolio for small molecule kinase inhibitor programsJones Day represented Ambit Biosciences in the development of patent portfolios related to small molecule kinase inhibitor programs and phage-displayed protein assays.
  • BD Diagnostics establishes patent portfolio for molecular diagnostic sepsis testsJones Day represented BD Diagnostics in the establishment of its patent portfolio for molecular diagnostic tests for early prediction of sepsis.
  • Additional Publications

    • February 2019
      Patent Eligibility Remains Uncertain — Especially for the Life Sciences — Even After Recent Federal Circuit Decisions and Efforts By the USPTO to Bring Clarity (Part Two of a Two-Part Article)
    • January 2019
      Patent Eligibility Remains Uncertain — Especially for the Life Sciences — Even After Recent Federal Circuit Decisions and Efforts By the USPTO to Bring Clarity (Part One of a Two-Part Article)
    • Autumn/Winter 2007
      Patentable Subject Matter in Biotechnology: Transgenic Animals and Higher Life Forms, Center for Advanced Study & Research on Intellectual Property (CASRIP) Newsletter, Volume 14, Issue 1
    • 2007
      Cooperative Binding of Acetaminophen and Caffeine within the P450 3A4 Active Site, coauthor, Chem Res Toxicol. 20, 1434-41
    • 2006
      NMR Studies of Ligand Binding to P450(eryF) Provides Insight into the Mechanism of Cooperativity, coauthor, Biochemistry 45, 1673-84
    • 2005
      Cooperative Binding of Midazolam with Testosterone and Alpha-Naphthoflavone within the CYP3A4 Ac-tive Site: A NMR T1 Paramagnetic Relaxation Study, coauthor, Biochemistry 44, 14143-51
    • 2005
      Software Pluralism, Shidler Center for Law, Commerce and Technology at the University of Washington School of Law
    • 2005
      The Thermodynamic Landscape of Testosterone Binding to Cytochrome P450 3A4: Ligand Binding and Spin State Equilibria, coauthor, Biochemistry 44, 1353-66
    • 2005
      Sites of Covalent Attachment of CYP4 Enzymes to Heme: Evidence for Microheterogeneity of P450 Heme Orientation, coauthor, Biochemistry 44, 13914-20
    • 2005
      Effects of Repeat Number on the Structure and Dynamics of the Core Peptide Epitope of Cancer Associated MUC1 Mucin: Application to Cancer Vaccine Design, coauthor, Biopolymers 77, 107-20
    • 2004
      Allosterism in the Elementary Steps of the Cytochrome P450 Reaction Cycle, coauthor, Drug. Met. Rev. 36, 219-30
    • 2003
      Interaction of a Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK with a Cross-Reactive Antibody: Changes in Backbone Dynamics Induced by Binding, coauthor, Biochemistry 42, 11334-46
    • 2003
      Probing the Conformational and Dynamical Effects of O-Glycosylation within the Immunodominant Region of a MUC1 Peptide Tumor Antigen, coauthor, J. Peptide Res. 61, 91-108
    • 2003
      Epitope Mapping of Antigenic MUC1 Peptides to Breast Cancer Antibody Fragment B27.29: A Heteronuclear NMR Study, coauthor, Biochemistry 42, 14293-305
    • 2002
      Effect of Glycosylation on Core Peptide Epitope Presentation to the Immune System: NMR Studies of MUC1 Glycopeptide-Antibody Interactions, coauthor, Biochemistry 41, 9946-61
    • 2001
      Structure of a Pilin Monomer from Pseudomonas aeruginosa: Implications for the Assembly of Pili, coauthor, J. Biol. Chem. 276, 24186-93
    • 2000
      Interaction of a Bacterially Expressed Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK with a Cross-reactive Antibody: Conformation of the Bound Peptide, coauthor, Biochemistry 39, 14847-64
    • 2000
      Glycosylations versus Conformational Preferences of Cancer Associated Mucin Core, coauthor, Glycoconjugate J. 17, 835-48
    • 2000
      Backbone Dynamics of a Bacterially Expressed Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK from Heteronuclear 1H-15N NMR Spctroscopy, coauthor, J. Biomol. NMR 17, 239-55
    • 1997
      Interaction of the Receptor Binding Domains of Pseudomonas aeruginosa Pili Strains PAK, PAO, KB7 and P1 to a Cross-Reactive Antibody and Receptor Analog: Implications for Synthetic Vaccine Design, coauthor, J. Mol. Biol. 267, 382-402
    • 1997
      Solution Secondary Structure of a Bacterially Expressed Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK: A Heteronuclear Multidimensional NMR Study, coauthor, Biochemistry 36, 12791-801
    • 1996
      Solution Conformation of an Immunogenic Peptide Derived from the Principal Neutralizing Determinant of the HIV-2 Envelope Glycoprotein gp 125, coauthor, Folding and Design 1, 157-65
    • 1996
      Lactam Bridge Stabilization of Alpha-helixes: The Role of Hydrophobicity in Controlling Dimeric versus Monomeric Alpha-helices, coauthor, Biochemistry 35, 10041-50
    • 1996
      NMR Solution Structure of the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain P1: Identification of a Beta-turn, coauthor, Int. J. Pept. Prote. Res. 48, 539-52
    • 1995
      A Comparison of NMR Solution Structures of the Receptor Binding Domains of Pseudomonas aeruginosa Pili Strains PAO, KB7 and PAK: Implications for Receptor Binding and Vaccine Design, coauthor, Biochemistry 34, 16255-68
    • 1994
      High Resolution Structures of Oxidized and Reduced Escherichia coli Thioredoxin, coauthor, Structure 2, 853-68
    • 1993
      Binding of a High-Energy Substrate Conformer in Antibody Catalysis, coauthor, Proc. Natl. Acad. Sci. USA. 90, 8663-67
    • 1993
      The Two-Dimensional Transferred Nuclear Overhauser Effect: Theory and Practice, coauthor, Annu. Rev. Biophys. Biomol. Struct. 22, 99-102
    • 1991
      Interaction of Troponin I and Troponin C: Use of the Two-Dimensional Transferred Nuclear Overhauser Effect to Determine the Structure of the Inhibitory Troponin I Peptide when Bound to Turkey Skeletal Troponin C, coauthor, J. Mol. Biol. 222, 405-21
    • 1991
      Theoretical Evaluation of the Two-Dimensional Transferred Nuclear Overhauser Effect, coauthor, J. Magn. Reson. 93, 77-92
    • 1991
      Effects of Internal Motions on the Development of the Two-Dimensional Transferred Nuclear Overhauser Effect, coauthor, J. Biomol. NMR 1, 391-402

    Speaking Engagements

    • March 27, 2019
      Intellectual Property and Plants
    • May 16, 2018
      Women in IP Speaker Series: Developing and Commercializing New Medicines: Do Patents Still Matter?
    • October 14, 2017
      Opportunities for Biosimilar Companies under the U.S. Legal System, 2017 Chinese Bioscience Association Annual Conference
    • September 6, 2017
      Introduction to Careers in Patent Law and Highlights of CRISPR/CAS Dispute; King Hall Intellectual Property Law Association University of California, Davis
    • April 3, 2017
      Patents and Basic Scientific Research: Discovery Versus Invention; 253rd ACS National Meeting and Exposition in San Fransisco, CA Chemistry & the Law (CHAL), "The Use of Scientific Information in IP-Related Matters"
    • May 26, 2014
      The Role of Patents in Biotechnology; "Translational Research Day," Li Ka Shing Applied Virology Institute University of Alberta
    • May 20, 2013
      Introduction to Patent Law II: Stem Cell Patents; Department of Biomedical and General Engineering; California Polytechnic State University
    • May 7, 2012
      Introduction to Patent Law I: Stem Cell Patents; Department of Biomedical and General Engineering; California Polytechnic State University
    • May 2012
      Women in IP Networking Happy Hour
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.